Open an account

Akoya Biosciences

AKYA · NASDAQ

Price unavailable right now.

No price history for this range.

About AKYA

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.

Employees
205
Headquarters
Marlborough, Massachusetts
Listed
Apr 16, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
akoyabio.com

AKYA key statistics

This section is temporarily unavailable. Refresh to try again.

AKYA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 17.0% on average.

  1. Q2 FY23: reported -$0.46 per share against an estimate of -$0.4517
  2. Q3 FY23: reported -$0.26 per share against an estimate of -$0.373
  3. Q4 FY23: reported -$0.22 per share against an estimate of -$0.2739
  4. Q1 FY24: reported -$0.48 per share against an estimate of -$0.2945
  5. Q2 FY24: reported -$0.27 per share against an estimate of -$0.2731
  6. Q3 FY24: reported -$0.21 per share against an estimate of -$0.2078
  7. Q4 FY24: reported -$0.17 per share against an estimate of -$0.1658
  8. Q1 FY25: reported -$0.32 per share against an estimate of -$0.2091

AKYA news

  • Press releasePRNewswire

    AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

  • Press releasePRNewswire

    Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

  • Press releasePRNewswire

    New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Akoya Biosciences Reports First Quarter 2025 Financial Results

  • Press releaseBusiness Wire

    AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

  • Press releaseBusiness Wire

    Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

Similar companies

Companies in the same industry as Akoya Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.